Ignyta is a precision medicine company focused on oncology. It aims to test, identify and treat patients with cancers harboring specific rare mutations. Ignyta’s lead molecule entrectinib is an orally bioavailable, CNS-active tyrosine kinase inhibitor targeting tumors that harbor ROS1 or NTRK fusions.
Per the agreement, Roche will commence a tender offer to acquire all of the outstanding shares of Ignyta’s common stock. After completion of the tender offer, Roche will acquire all remaining shares through a second step merger.
The deal is expected to close in the first half of 2018.
More articles on data analytics & precision medicine:
FTC issues privacy warning over direct-to-consumer genetic tests
Former IBM Watson oncologist named VP of precision medicine startup: 4 things to know
UNC researchers find Watson for Genomics tech useful for identifying potential therapies
